Business Wire

Orca Bio Presents New Clinical Data on its Pipeline of High-Precision Cell Therapies including Orca-Q® Without GvHD Prophylaxis and Orca-T/CAR-T Combination Therapy at the ...

Orca-Q, Orca Bio’s second investigational allogeneic T-cell immunotherapy, showed low rates of acute and chronic GvHD, infections and non-relapse mortality with and without GvHD prophylaxis Orca-T ...
Business Wire

Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting

– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control ...
EurekAlert!

18th Annual Q-Bio Conference: Global scholars explore new Frontiers in quantitative biology

The Q-Bio conference drew over 230 global researchers from countries including the U.S., U.K., France, India, Japan, Chile, and China. Themed "Predictive Modeling and Quantitative Principles in ...
Times Argus

Orca Bio Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ...
Pharmabiz

Orca Bio’s Orca-Q receives US FDA’s RMAT designation for treatment of high-risk hematologic malignancies

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, announced that the US Food and Drug Administration (FDA) has granted ...